ASH 2023 | The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the efficacy of daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVD) in patients with t(11;14) multiple myeloma. The t(11;14) subset is historically associated with an inferior treatment response compared to other patients with the disease. However, the addition of daratumumab to RVD treatment has increased progression-free survival (PFS), deepening responses in this subset. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Novartis, Janssen
Consultancy: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc.
Advisory Committee: TG Therapeutics Inc:
Board of Directors with Stock: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Contracted Research: Janssen
